AFFILIATIONS
1 Sarah Cannon Research Institute, Nashville, Tennessee, United States
2 AstraZeneca, Gaithersburg, Maryland, United States
3 Vinzent Strategies LLC, Blue Bell, Pennsylvania, United States
4 Vinzent Strategies LLC, Blue Bell, Pennsylvania, United States
5 AstraZeneca, Cambridge, United Kingdom
6 AstraZeneca, Gaithersburg, Maryland, United States
ABSTRACT
Background: Therapy approaches for elderly pts with DLBCL are often fragmented, leading to uncertainty about efficacy and tolerability of treatments. Real-world evidence on treatment access, utilization, sequencing, and effectiveness is sparse. This analysis characterized real-world treatment patterns and clinical outcomes over time in pts ≥65 years old with DLBCL.
Methods: This observational, retrospective cohort study used the electronic medical record COTA database, which contains longitudinal data on cancer diagnosis, treatment, and outcomes from pts in diverse US care settings. Pts ≥65 years old with confirmed DLBCL, diagnosed before Nov 22, 2025 who initiated first-line (1L) therapy on/after Jan 1, 2018 up to May 22, 2026 were included. Primary objective: to characterize treatment patterns until death, loss to follow-up, or data cutoff. Treatment categories included chemoimmunotherapy (CIT), chimeric antigen receptor T-cell (CAR-T) therapy, antibody drug conjugates (ADCs)±CIT, and T-cell engagers (TCEs; mono/combination therapy). Treatment distribution was stratified by line of treatment (LOT; 1L–4L), site of care (community vs academic), age (65–74/75–80/>80 years), and treatment initiation (1L before vs after Jan 1, 2022). Secondary objectives: to assess overall survival (OS) and time to next treatment or death (TTNTD).
Results: Overall, 3194 pts initiated 1L therapy; 665, 298, and 130 pts progressed to 2L, 3L, and 4L, respectively. At 1L initiation, median age (range) was 74 (65–91) years; 20% of pts were >80 years old; 54% were male; 32% were non-white. Most pts (95%) had an Eastern Cooperative Oncology Group performance score 0–2; 46% had an International Prognostic Index score ≤2. Median follow-up from diagnosis was 1.9 years. After 1L treatment, 1787 (56%) pts were lost to follow-up; 128 (4%)/614 (19%) pts died with/without a progression event from 1L to 2L, respectively.
CIT was the most-used treatment (1L, 92%), but usage declined substantially across later LOTs (2L, 53%; 3L, 22%; 4L, 14%). ADC±CIT was used less frequently in 1L (5%); its usage increased in subsequent LOTs (2L, 17%; 3L, 21%; 4L, 22%). Use of newer therapies increased with advancing LOT (CAR-T: 2L, 5%; 3L, 25%; 4L, 25%; TCEs: 2L, 1%; 3L, 7%; 4L, 9%).
CIT was used more often at community vs academic sites across LOTs, apart from 4L (9% vs 18%), while ADC±CIT use was generally comparable across care settings. CAR-T usage was less prominent at community vs academic sites (3L, 19% vs 30%; 4L, 18% vs 31%). TCE use was also less common at community vs academic sites in 3L (3% vs 10%), but not in 4L (9% vs 8%).
CIT usage was greater for pts aged 65–74 and 75–80 vs >80 years across all LOTs, apart from 4L, where it was more common in the 75–80 group vs 65–74 and >80 groups. CAR-T use was more common in pts aged 65–74 (2L, 7%; 3L, 31%; 4L, 31%) across all LOTs vs 75–80 (2L, 3%; 3L, 22%; 4L, 19%) and >80 years (2L, 2%; 3L, 8%; 4L, 10%). TCE use was comparable across all ages in 2L, more common for pts aged >80 years old in 3L, and most used for pts aged 65–74 years in 4L.
CIT was more commonly used in most LOTs before 2022, compared with during/after 2022, apart from 4L where CIT use was greater during/after 2022 (26% vs 10%). Use of newer therapies, such as CAR-T and TCEs, increased in/after 2022 in all LOTs, compared with before 2022.
Median OS (95% confidence interval [CI]) for the 1L cohort was 73 (66–79) months. Median OS (95% CI) decreased from 86 (80–not evaluable [NE]) to 65 (53–NE), and 45 (34–54) months for pts aged 65–74, 75–80, and >80 years, respectively. Median TTNTD (95% CI) was 51 (46–57) months for 1L and declined across later LOTs: 5 (4–6), 5 (4–6), and 5 (4–7) months for 2L, 3L, and 4L, respectively.
Conclusions: This analysis provides detailed insights into the evolution of the DLBCL treatment landscape for older pts. For pts aged ≥65 years old with DLBCL, treatment patterns differed by LOT, age, practice setting, and date of treatment initiation. CIT use was consistent across all LOTs, despite emergence of novel therapies. CAR-T and TCE use increased from 2022 onwards and was more common at academic vs community sites and for pts aged 65–74 years old, however, usage in later LOTs remained low compared with standard therapies. Clinical outcomes worsened with age and advancing LOT. These findings highlight an ongoing unmet need and potential for advancement of novel therapies to improve care of elderly pts.
DISCLOSURES
Krish Patel, MD: Kite - Honoraria; Pfizer - Honoraria; ADC Therapeutics - Honoraria; Lilly - Honoraria; Genentech/Roche - Honoraria; Merck - Honoraria; BeiGene - Honoraria; Bristol-Myers Squibb - Honoraria; AbbVie - Honoraria; AstraZeneca - Honoraria; Caribou Biosciences - Honoraria; Fate Therapeutics - Research Funding; Nurix - Research Funding; Mittenyi Biomedicine - Research Funding; Bristol-Myers Squibb - Research Funding; Pfizer - Research Funding; AvenCell - Research Funding; AstraZeneca - Research Funding; Immunome - Research Funding; Kite - Research Funding; MEI Pharma - Research Funding; Merck - Research Funding; Janssen - Research Funding; Xencor - Research Funding; Sana Biotechnology - Research Funding; Genentech/Roche - Research Funding; Pharmacyclics - Research Funding; Indapta Therapeutics - Research Funding; Lilly - Research Funding; Arvinas - Research Funding; Treeline Biosciences - Research Funding; Ono Pharmaceutical - Research Funding; CRISPR Therapeutics - Research Funding; Loxo Oncology - Research Funding; AbbVie - Research Funding; Lyell Immunopharma - Research Funding; Umoja Biopharma - Research Funding; TORL Biotherapeutics - Research Funding; Adicet - Research Funding; Adaptive Biotechnologies - Research Funding; Bristol-Myers Squibb - Consultancy (Includes expert testimony); Foresight Diagnostics - Consultancy (Includes expert testimony); ADC Therapeutics - Consultancy (Includes expert testimony); BioNTech - Consultancy (Includes expert testimony); BeOne Medicines - Consultancy (Includes expert testimony); AstraZeneca - Consultancy (Includes expert testimony); Legend Biotech - Consultancy (Includes expert testimony); Janssen - Consultancy (Includes expert testimony); Lyell Immunopharma - Consultancy (Includes expert testimony); Avencell Therapeutics - Consultancy (Includes expert testimony); Genentech/Roche - Consultancy (Includes expert testimony); Lilly - Consultancy (Includes expert testimony); Century Therapeutics - Consultancy (Includes expert testimony); Adaptive Biotechnologies - Consultancy (Includes expert testimony); Kyverna Therapeutics - Consultancy (Includes expert testimony); Immunome - Consultancy (Includes expert testimony); Arcus Biosciences - Consultancy (Includes expert testimony); Genmab - Consultancy (Includes expert testimony); Merck - Consultancy (Includes expert testimony); Caribou Biosciences - Consultancy (Includes expert testimony); Sanofi - Consultancy (Includes expert testimony); AvenCell - Consultancy (Includes expert testimony); BicycleTx - Consultancy (Includes expert testimony); AbbVie - Consultancy (Includes expert testimony)